Drugs / T-DXd
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07417241 Comparator | Mar 2026 → Jan 2029 expected | HER2 positive breast carcinoma | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T-DXd | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07417241 ↗ |
| Route | Intravenous | “administered as an intravenous infusion” NCT07417241 ↗ |